Compare Tango Therapeutics Inc. (TNGX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Williams-Sonoma, Inc. — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Williams-Sonoma, Inc. trades at $243.02 (market cap $28.26B). The key difference: Williams-Sonoma, Inc. is far larger — about 7.6× Tango Therapeutics Inc.'s market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Williams-Sonoma, Inc. for 59 Days on average.
| TNGX | WSM | |
|---|---|---|
Market Cap | $3.74B | $28.26B |
Volume | 3,438,781 | 1,108,410 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.90 | $251.81 |
52-Week Low | $7.50 | $168.64 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.76B | $28.76B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Williams-Sonoma (WSM) trades at $239.98, up 0.47% today, reflecting strong momentum near its consensus price target of $246.31. The stock shows bullish technical signals with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.10 versus $2.08 expected. Fundamentals are robust with a net income margin of 14.73% and ROE of 54.96%, supported by strategic initiatives like new store openings and collaborations.
The outlook remains positive with raised full-year guidance and market share gains in a flat industry, though risks include housing market sensitivity and high valuation multiples. Analyst consensus leans Hold (57.15%) with upside potential to the high target of $275, but investor caution is warranted given the stock's premium pricing and economic cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
